Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three opioid analgesics—fentanyl, methadone, and morphine. All three are potent opioids used primarily for the management of severe pain that cannot be controlled by other means. Fentanyl is a synthetic opioid approximately 100 times more potent than morphine and is used for pain relief and anesthesia[3][9]. Methadone is a synthetic opioid with unique properties as both a full µ-opioid receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist; it is used for severe pain as well as in the treatment of opioid dependence[5]. Morphine, derived from opium poppy, acts mainly as a µ-opioid receptor agonist to provide analgesia[2][6]. The combination would have additive or potentially synergistic effects on pain relief but also significantly increases the risk of adverse effects such as respiratory depression, sedation, overdose, and death due to their overlapping mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + methadone + morphine.